Johnson & Johnson Reports Q2 2025 Results; Raises 2025 Outlook
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/25/2026
- Nasdaq, S&P end lower as tech stocks fall
- Micron posts record profit as AI memory demand fuels explosive growth
- Brent settles at lowest since before start of Iran war as more tankers exit Hormuz
- All eyes on Micron earnings tonight as sell-off raises stakes for AI memory trade
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
Johnson & Johnson (JNJ) PT Raised to $185 at Goldman Sachs
July 17, 2025 6:07 AM EDTGoldman Sachs analyst Asad Haider raised the price target on Johnson & Johnson (NYSE: JNJ) to $185.00 (from $177.00) while maintaining a Buy rating.
The analyst comments "In a backdrop where we had that noted our investor conversations suggest sentiment shifting slightly more positive on the tactical setup for US pharma into 2Q earnings season (see: link), JNJ shares... More
Johnson & Johnson (JNJ) Tops Q2 EPS by 9c, Beats on Revenue; Offers Strong FY25 Guidance
July 16, 2025 6:21 AM EDTJohnson & Johnson (NYSE: JNJ) reported Q2 EPS of $2.77, $0.09 better than the analyst estimate of $2.68. Revenue for the quarter came in at $23.74 billion versus the consensus estimate of $22.86 billion.
GUIDANCE:
Johnson & Johnson sees FY2025 EPS of $10.63-$10.73, versus the consensus of $10.61.... More
